HOXA9

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Homeobox A9
Protein HOXA9 PDB 1puf.png
PDB rendering based on 1puf.
Available structures
PDB Ortholog search: PDBe, RCSB
Identifiers
Symbols HOXA9 ; ABD-B; HOX1; HOX1.7; HOX1G
External IDs OMIM142956 MGI96180 HomoloGene7766 GeneCards: HOXA9 Gene
RNA expression pattern
PBB GE HOXA9 214651 s at tn.png
PBB GE HOXA9 209905 at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 3205 15405
Ensembl ENSG00000078399 ENSMUSG00000038227
UniProt P31269 P09631
RefSeq (mRNA) NM_152739 NM_001277238
RefSeq (protein) NP_689952 NP_001264167
Location (UCSC) Chr 7:
27.2 – 27.21 Mb
Chr 6:
52.22 – 52.23 Mb
PubMed search [1] [2]

Homeobox protein Hox-A9 is a protein that in humans is encoded by the HOXA9 gene.[1][2]

In vertebrates, the genes encoding the class of transcription factors called homeobox genes are found in clusters named A, B, C, and D on four separate chromosomes. Expression of these proteins is spatially and temporally regulated during embryonic development. This gene is part of the A cluster on chromosome 7 and encodes a DNA-binding transcription factor which may regulate gene expression, morphogenesis, and differentiation. This gene is highly similar to the abdominal-B (Abd-B) gene of Drosophila. A specific translocation event which causes a fusion between this gene and the NUP98 gene has been associated with myeloid leukemogenesis.[3]

As HOXA9 dysfunction has been implicated in acute myeloid leukemia,[4] and expression of the gene has been shown to differ markedly between erythrocyte lineages of different stages of development,[5] the gene is of particular interest from a hematopoietic perspective.

Function[edit]

Role in hematopoiesis[edit]

As HOXA9 is part of the homeobox family, involved in setting the body plans of animals,[6] it is likely that HOXA9 would display increased expression in cells with higher differentiation potentials. Indeed in the hematopoietic lineage, it has been found that HOXA9 is preferentially expressed in hematopoietic stem cells (HSCs), and is down-regulated as the cell differentiates and matures further.[7]

HOXA9 knockout mice have been shown to develop a reduction in the number of circulating common myeloid progenitor cells, which differentiate into erythroid progenitor cells.[8] Interestingly, the same study indicated that HOXA9 deficiencies specifically affected the granulocyte lineage of the common myeloid progenitor, and it was in HOXA7 knockout mice where the erythroid lineage was affected; however, ErythronDB shows HOXA7 as being insignificantly expressed in all stages of each erythroid lineage.[5] This is something that needs to be investigated further, and could shed light on the interactions between the genes in the HOXA family.

Another study found that HOXA9 knockout HSCs displayed a 5-fold impairment to proliferation rate in vitro, as well as delayed maturation to committed progenitors, specifically myeloid maturation, and that normal proliferation and differentiation rates could be reinstated by reintroducing a HOXA9 vector into the culture.[9] In vivo, lethally irradiated mice with transplanted HOXA9 knockout HSCs displayed a 4-fold to 12-fold reduction in repopulating ability. Furthermore, they developed 60% less myeloid and erythroid colonies in the bone marrow when compared to the wild type.[10] Furthermore, transgenic mice with overexpressed HOXA9 developed a 15-fold increase in the amount of committed progenitor cells in the bone marrow,[11] indicating that overexpressed HOXA9 induces expansion of the HSC population without disrupting differentiation.

From these results, it appears that HOXA9 is important in maintaining HSC populations, as well as guiding their differentiation, especially towards myeloid (erythroid and granulocyte) lineages.

Expression in adult, fetal and embryonic stages[edit]

Throughout the development of a mammal, there are three distinct stages of erythrocyte formation – embryonic, fetal and adult. Adult erythrocytes are the most common blood cell type in mammals, and their characteristic biconcave shape, 7-8 µm diameter and enucleation are amongst the greatest commonalities between mammalian species.[12] However, primitive and fetal erythrocytes, which circulate during early stages of development, are markedly different from their adult counterparts, most obviously through their larger size, shorter lifespan, nucleation, containment of different hemoglobin chains, and higher oxygen affinity.[13] The reasons for and functions of these differences are not well established.

HOXA9 is a candidate for one of the genes responsible for these morphological differences between the erythrocyte lineages, as it is expressed differently in each lineage.[5] In primitive erythrocyte precursors, HOXA9 expression is almost zero. It increases slightly in the fetal stage, and then it is expressed highly in the adult erythrocyte precursors. This expression profile links to the importance of HOXA9 in the HSC, as it mirrors the fact that HSCs are absent in the developing embryo, undergoing initial production in the fetal stage, and are vital in the adult. Furthermore, in the fetal and adult precursors, not all precursor stages display HOXA9 expression. Most of the expression is in the proerythroblast (P) stage, and a minor amount in the basophilic erythroblast (B) stage. There is almost zero expression in the orthonormoblast (O) and reticulocyte (R) stages.[5] P and B are the first two stages of committed differentiation in the erythrocyte lineage, and this implies that HOXA9 may only be involved in the differentiation and proliferation of HSCs, rather than the erythrocyte maturation process.

Clinical significance[edit]

Role in acute myeloid leukemia[edit]

Ordinarily, HOXA9 is expressed on chromosome 7 and the nucleoporin gene NUP98 is expressed on chromosome 11. However, a gene translocation which sometimes occurs in humans moves NUP98 onto chromosome 7, where it fuses with HOXA9 to form the NUP98-HOXA9 oncogene.[4] This oncogene has been widely implicated in acute myeloid leukemia (AML), and expression of this oncogene is the single most highly correlating factor for poor AML prognosis.[11] The oncogene has been found to increase proliferative rates of HSCs whilst impairing their differentiation.

The HOXA9 fusion oncogene causes an 8 times greater proliferation rate of HSCs after 5 weeks of cell culture when compared to control cells,[14] and doubles the period of time over which HSCs can self-renew to an average of 54.3 days, compared to control human HSCs which stopped proliferating after 27.3 days.[15]

There are conflicting results regarding the effect of the oncogene on the differentiation of HSCs into the erythroid lineage. One study observed that the oncogene had a detrimental effect on the differentiation of HSCs, especially in the erythroid lineage, as proerythroblast colonies derived in vitro from mutated HSCs were fewer in number when compared to those derived from control HSCs, regardless of growth factors such as erythropoietin and interleukins which were introduced into the cultures.[14] However, another study noted that the erythroid colonies were twice as populated in cultures of oncogene HSCs when compared to control HSCs.[15] It is possible that these differing observations are due to a delayed differentiation of HSCs affected by the oncogene. The study which observed an increase in erythroid cell number noted that this proliferative effect could only be observed after around 3 weeks, and before this, cell numbers were comparable if not lower for the oncogene culture.[15] The study observing a decreased number of cells did not quote the time of measurement, so if it was within three weeks of the culture, the reduced number may be attributed to this delay.

Morphology alteration[edit]

Proerythroblasts formed in the densely populated colonies of oncogene HSC cultures are strikingly different from those formed in the control colonies. By staining the colonies with giemsa, the oncogene-derived cells were shown to be non-hemoglobinized, larger, much less uniform in shape and had a distinctly large nucleus.[15] These are some of the key morphological differences between primitive erythrocytes and adult erythrocytes. Thus, the NUP98-HOXA9 fusion may give rise to a new population of primitive erythrocytes in cases of AML, and by investigating the various proteins coded by this oncogene, it may be possible to not only establish some molecular causes of AML, but also identify some crucial proteins involved in early erythropoiesis which are absent during adult erythropoiesis.

Pure erythroid leukemia[edit]

There exists a rare form of AML, pure erythroid leukemia, where only the erythroid precursors of myeloid progenitors are leukemic, and not the granulocyte precursors. In this form of AML, levels of erythroblasts can reach up to 94.8% of all nucleated cells in the bone marrow,[16] and the immature forms of the erythroblasts, the proerythroblasts and basophilic erythroblasts, are more commonly found.[17] One study noted that in control leukemic groups with general AML, immature erythroblasts accounted for 8% of all erythroid cells, but in a group with pure erythroid leukemia, this number was a minimum of 40%, and ranged up to 83%.[17] Furthermore, in the case of pure erythroid leukemia, the immature erythrocytes are most morphologically affected, being larger and sometimes bi- or tri-nucleic.[17] Hence the most affected stages of erythrocyte development in pure erythroid leukemia are the same stages in which HOXA9 expression is greatest.

Interactions[edit]

HOXA9 has been shown to interact with:

HOXA9 expression is regulated by several genes, including UTX, WHSC1, MLL and MEN1.[21] UTX, MLL and WHSC1 code for protein methylation and demethylation activity,[5] specifically for the histone methyltransferase complex, of which increased levels have been shown to correlate with higher HOXA9 expression.[22] MEN1 codes for the tumour suppressing protein menin, and lower menin levels as a result of MEN1 excision correlate with low HOXA9 expression.[23] UTX and WHSC1 also display similar expression patterns to HOXA9, being lowest in the embryonic erythrocyte lineage, higher in the fetal stage and showing highest expression in the adult stage.[5] MLL and MEN1, however, show consistent expression through each erythroid lineage,[5] and it is possible that some other transcription factor may be interfering with the actions of these genes on HOXA9 during the embryonic stage.

HOXA9 itself regulates a vast array of genes, such as Flt3, Erg, Myb and Lmo2,[24] all of which exhibit the characteristic increasing expression pattern through the erythroid lineages displayed by HOXA9.[5] Furthermore, mutations in each of these genes have been implicated in cancers. Flt3 duplication is observed in 20% of AML cases, and along with NUP98 translocation, it is associated with a poor prognosis.[25] Erg and Myb are part of two families of transcription factors which, when mutated, correlate strongly with prostate cancer and myeloblastosis respectively.[26] Lmo2 is associated with T-cell leukemias, and is also essential to erythropoiesis in early developmental stages, as Lmo2 knockout mice experience yolk sac erythropoiesis failure and the embryo dies around 10.5 days post coitus.[27] This seems to contradict with the observed expression of Lmo2 being significantly lower in embryonic stages compared to fetal and adult stages.[5]

Other genes have already been shown to co-operate with NUP98-HOXA9 and increase their activity, such as Dnalc4, Fcgr2b, FcrI and Con1.[28] This particular study utilized reverse transcription polymerase chain reaction to measure changes in gene expression.

See also[edit]

References[edit]

  1. ^ McAlpine PJ, Shows TB (Aug 1990). "Nomenclature for human homeobox genes". Genomics 7 (3): 460. doi:10.1016/0888-7543(90)90186-X. PMID 1973146. 
  2. ^ Scott MP (Dec 1992). "Vertebrate homeobox gene nomenclature". Cell 71 (4): 551–3. doi:10.1016/0092-8674(92)90588-4. PMID 1358459. 
  3. ^ "Entrez Gene: HOXA9 homeobox A9". 
  4. ^ a b Nakamura T, Largaespada DA, Lee MP, Johnson LA, Ohyashiki K, Toyama K, Chen SJ, Willman CL, Chen IM, Feinberg AP, Jenkins NA, Copeland NG, Shaughnessy JD (February 1996). "Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukemia". Nat. Genet. 12 (2): 154–8. doi:10.1038/ng0296-154. PMID 8563753. 
  5. ^ a b c d e f g h i Kingsley PD, Greenfest-Allen E, Frame JM, Bushnell TP, Malik J, McGrath KE, Stoeckert CJ, Palis J (February 2013). "Ontogeny of erythroid gene expression". Blood 121 (6): e5–e13. doi:10.1182/blood-2012-04-422394. PMC 3567347. PMID 23243273. 
  6. ^ Chisaka O, Capecchi MR (April 1991). "Regionally restricted developmental defects resulting from targeted disruption of the mouse homeobox gene hox-1.5". Nature 350 (6318): 473–9. doi:10.1038/350473a0. PMID 1673020. 
  7. ^ Argiropoulos B, Humphries RK (October 2007). "Hox genes in hematopoiesis and leukemogenesis". Oncogene 26 (47): 6766–76. doi:10.1038/sj.onc.1210760. PMID 17934484. 
  8. ^ So CW, Karsunky H, Wong P, Weissman IL, Cleary ML (April 2004). "Leukemic transformation of hematopoietic progenitors by MLL-GAS7 in the absence of Hoxa7 or Hoxa9". Blood 103 (8): 3192–9. doi:10.1182/blood-2003-10-3722. PMID 15070702. 
  9. ^ Lawrence HJ, Christensen J, Fong S, Hu YL, Weissman I, Sauvageau G, Humphries RK, Largman C (December 2005). "Loss of expression of the Hoxa-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells". Blood 106 (12): 3988–94. doi:10.1182/blood-2005-05-2003. PMC 1895111. PMID 16091451. 
  10. ^ Lawrence HJ, Helgason CD, Sauvageau G, Fong S, Izon DJ, Humphries RK, Largman C (March 1997). "Mice bearing a targeted interruption of the homeobox gene HOXA9 have defects in myeloid, erythroid, and lymphoid hematopoiesis". Blood 89 (6): 1922–30. PMID 9058712. 
  11. ^ a b Thorsteinsdottir U, Mamo A, Kroon E, Jerome L, Bijl J, Lawrence HJ, Humphries K, Sauvageau G (January 2002). "Overexpression of the myeloid leukemia-associated Hoxa9 gene in bone marrow cells induces stem cell expansion". Blood 99 (1): 121–9. doi:10.1182/blood.V99.1.121. PMID 11756161. 
  12. ^ Pierigè F, Serafini S, Rossi L, Magnani M (January 2008). "Cell-based drug delivery". Adv. Drug Deliv. Rev. 60 (2): 286–95. doi:10.1016/j.addr.2007.08.029. PMID 17997501. 
  13. ^ Crowley J, Ways P, Jones JW (June 1965). "Human fetal erythrocyte and plasma lipids". J. Clin. Invest. 44 (6): 989–98. doi:10.1172/JCI105216. PMC 292579. PMID 14322033. 
  14. ^ a b Chung KY, Morrone G, Schuringa JJ, Plasilova M, Shieh JH, Zhang Y, Zhou P, Moore MA (December 2006). "Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation". Cancer Res. 66 (24): 11781–91. doi:10.1158/0008-5472.CAN-06-0706. PMID 17178874. 
  15. ^ a b c d Takeda A, Goolsby C, Yaseen NR (July 2006). "NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells". Cancer Res. 66 (13): 6628–37. doi:10.1158/0008-5472.CAN-06-0458. PMID 16818636. 
  16. ^ Kitagawa J, Hara T, Tsurumi H, Oyama M, Moriwaki H (2009). "Pure erythroid leukemia with hemophagocytosis". Intern. Med. 48 (18): 1695–8. doi:10.2169/internalmedicine.48.1798. PMID 19755777. 
  17. ^ a b c Liu W, Hasserjian RP, Hu Y, Zhang L, Miranda RN, Medeiros LJ, Wang SA (March 2011). "Pure erythroid leukemia: a reassessment of the entity using the 2008 World Health Organization classification". Mod. Pathol. 24 (3): 375–83. doi:10.1038/modpathol.2010.194. PMID 21102413. 
  18. ^ Shen WF, Montgomery JC, Rozenfeld S, Moskow JJ, Lawrence HJ, Buchberg AM, Largman C (November 1997). "AbdB-like Hox proteins stabilize DNA binding by the Meis1 homeodomain proteins". Mol. Cell. Biol. 17 (11): 6448–58. PMC 232497. PMID 9343407. 
  19. ^ a b Shen WF, Rozenfeld S, Kwong A, Köm ves LG, Lawrence HJ, Largman C (April 1999). "HOXA9 forms triple complexes with PBX2 and MEIS1 in myeloid cells". Mol. Cell. Biol. 19 (4): 3051–61. PMC 84099. PMID 10082572. 
  20. ^ Rual JF, Venkatesan K, Hao T, Hirozane-Kishikawa T, Dricot A, Li N, Berriz GF, Gibbons FD, Dreze M, Ayivi-Guedehoussou N, Klitgord N, Simon C, Boxem M, Milstein S, Rosenberg J, Goldberg DS, Zhang LV, Wong SL, Franklin G, Li S, Albala JS, Lim J, Fraughton C, Llamosas E, Cevik S, Bex C, Lamesch P, Sikorski RS, Vandenhaute J, Zoghbi HY, Smolyar A, Bosak S, Sequerra R, Doucette-Stamm L, Cusick ME, Hill DE, Roth FP, Vidal M (October 2005). "Towards a proteome-scale map of the human protein-protein interaction network". Nature 437 (7062): 1173–8. doi:10.1038/nature04209. PMID 16189514. 
  21. ^ Chapman MA, Lawrence MS, Keats JJ, Cibulskis K, Sougnez C, Schinzel AC, Harview CL, Brunet JP, Ahmann GJ, Adli M, Anderson KC, Ardlie KG, Auclair D, Baker A, Bergsagel PL, Bernstein BE, Drier Y, Fonseca R, Gabriel SB, Hofmeister CC, Jagannath S, Jakubowiak AJ, Krishnan A, Levy J, Liefeld T, Lonial S, Mahan S, Mfuko B, Monti S, Perkins LM, Onofrio R, Pugh TJ, Rajkumar SV, Ramos AH, Siegel DS, Sivachenko A, Stewart AK, Trudel S, Vij R, Voet D, Winckler W, Zimmerman T, Carpten J, Trent J, Hahn WC, Garraway LA, Meyerson M, Lander ES, Getz G, Golub TR (March 2011). "Initial genome sequencing and analysis of multiple myeloma". Nature 471 (7339): 467–72. doi:10.1038/nature09837. PMC 3560292. PMID 21430775. 
  22. ^ Yan J, Chen YX, Desmond A, Silva A, Yang Y, Wang H, Hua X (2006). "Cdx4 and menin co-regulate Hoxa9 expression in hematopoietic cells". In Arendt, Christopher. PLoS ONE 1 (1): e47. doi:10.1371/journal.pone.0000047. PMC 1762371. PMID 17183676. 
  23. ^ Chen YX, Yan J, Keeshan K, Tubbs AT, Wang H, Silva A, Brown EJ, Hess JL, Pear WS, Hua X (January 2006). "The tumor suppressor menin regulates hematopoiesis and myeloid transformation by influencing Hox gene expression". Proc. Natl. Acad. Sci. U.S.A. 103 (4): 1018–23. doi:10.1073/pnas.0510347103. PMC 1326489. PMID 16415155. 
  24. ^ Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C, Robertson G, MacDonald J, Cezard T, Bilenky M, Thiessen N, Zhao Y, Zeng T, Hirst M, Hero A, Jones S, Hess JL (January 2012). "Identification and characterization of Hoxa9 binding sites in hematopoietic cells". Blood 119 (2): 388–98. doi:10.1182/blood-2011-03-341081. PMC 3257007. PMID 22072553. 
  25. ^ Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T (April 2001). "Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies". Blood 97 (8): 2434–9. doi:10.1182/blood.V97.8.2434. PMID 11290608. 
  26. ^ Stenman G, Andersson MK, Andrén Y (August 2010). "New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer". Cell Cycle 9 (15): 2986–95. doi:10.4161/cc.9.15.12515. PMC 3040924. PMID 20647765. 
  27. ^ Warren AJ, Colledge WH, Carlton MB, Evans MJ, Smith AJ, Rabbitts TH (July 1994). "The oncogenic cysteine-rich LIM domain protein rbtn2 is essential for erythroid development". Cell 78 (1): 45–57. doi:10.1016/0092-8674(94)90571-1. PMID 8033210. 
  28. ^ Iwasaki M, Kuwata T, Yamazaki Y, Jenkins NA, Copeland NG, Osato M, Ito Y, Kroon E, Sauvageau G, Nakamura T (January 2005). "Identification of cooperative genes for NUP98-HOXA9 in myeloid leukemogenesis using a mouse model". Blood 105 (2): 784–93. doi:10.1182/blood-2004-04-1508. PMID 15454493. 

External links[edit]

This article incorporates text from the United States National Library of Medicine, which is in the public domain.